A THC-loaded stem cell-derived exosome skin homeostatic agent and its preparation method and application
Through the synergistic effect of stem cell-derived exosome skin homeostasis agents and Ikedoin, the existing limited methods for treating inflammatory skin diseases have been solved, significantly improved the treatment effect, and achieved the goal of inflammatory skin diseases. Effectively improve.
Patent Information
- Application Number
- CN202211149297.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-21
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2042-09-21
AI Technical Summary
There are limited existing methods for treating inflammatory skin diseases, especially patients with ineffective local steroids or systemic immunosuppressants lack effective treatment options, and the components of stem cell-derived exosomes are complex and the mechanism of action is unclear, making it difficult to promote in clinical practice.
Develop a stem cell-derived exosome skin homeostasis agent loaded with tetrahydrocurcumin (THC), combined with Ektoin, through scientific proportioning, no need to add preservatives, significantly improve the in vitro stability of exosomes and pass through cells , animal and human trials have verified their therapeutic effects.
This skin homeostasis agent effectively prevents, inhibits or improves damaged skin barrier function. By enhancing the secretion of skin barrier proteins, maintains the normal detoxification function of skin cells, improves the imbalance of the internal skin homeostasis, and significantly improves the effect of treating inflammatory skin diseases.
Smart Images

Figure CN116196333B_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine, and specifically relates to a THC-loaded stem cell-derived exosome skin homeostasis agent, and a preparation method and application thereof. Background Art
[0002] Inflammatory skin diseases, such as atopic dermatitis (AD), psoriasis, scleroderma, acne, and autoimmune diseases affecting the skin, including graft-versus-host disease (GvHD) and systemic lupus erythematosus (SLE), have led to a serious deterioration in quality of life and have become one of the health problems worldwide. Rapid industrialization has increased the production of carbon dioxide and various waste gases, resulting in various forms of air pollution and a high-allergen environment. Diesel exhaust particles can directly induce mast cells (MCs) to release histamine and aggravate allergic symptoms, resulting in an annual increase in the number of patients with inflammatory skin diseases. Itching, insomnia, and long-term discomfort lead to a decline in the quality of life of patients with inflammatory skin, causing great psychological and economic burdens. However, there are limited treatments for these diseases, especially for patients who do not respond to topical steroids or systemic immunosuppressants, and there is no better treatment in clinical practice. Some antibody drugs have the disadvantages of large side effects of repeated administration and long-term administration for several months to achieve therapeutic effects.
[0003] Mesenchymal stem cells (MSCs), the main stem cells in the field of cell therapy, have been used clinically for more than 10 years and are a safe and effective biological agent for the treatment of various intractable autoimmune and inflammatory diseases. Early studies reported that MSCs can migrate to the site of injury and then differentiate into functional cells, or fuse with damaged cells to regenerate damaged tissues. To date, there is still a lack of evidence that MSCs can effectively differentiate at the site of injury and participate in the treatment mechanism. Studies have shown that MSCs can release soluble immunomodulatory factors such as IDO (indoleamine-2, 3-dioxygenase, indoleamine 2, 3-dioxygenase), PGE2 (prostaglandin E2), TSG6 (tumour necrosis factor (TNF)-stimulated gene 6 protein) and exosomes through paracrine mechanisms to help restore a healthy skin microenvironment, promote tissue repair, and participate in immune regulation. These bioactive substances are also called the secretome of MSC (MSC-Sec), which has brought development to "cell-free" treatment. Two clinical trials have confirmed the potential of MSC-Sec in the treatment of inflammatory skin diseases, with positive results of improving the skin barrier function of AD patients and reducing psoriasis plaques in patients with psoriasis scalp. However, MSC-Sec contains a variety of cytokines, soluble proteins, metabolites, etc. secreted by MSC, with complex components and unclear mechanisms of action, and is not suitable for further promotion and use in clinical practice. Most studies have shown that the exosome (exo) component in MSC-Sec is its main active ingredient for tissue repair and immunomodulation. Exosomes are a type of extracellular vesicle with a diameter of 30-150 nm. They circulate in body fluids, enter nearby or distant target cells, and promote cell-to-cell communication by delivering functional mRNA, miRNA, proteins and lipids through direct fusion, endocytosis and binding of receptor ligands, thereby participating in a variety of physiological and pathological processes in the human body, such as antigen presentation, immune response and cell differentiation. Studies have shown that exosomes secreted by umbilical cord mesenchymal stem cells (UCMSC-exo) have unique immunomodulatory properties, which is a potential mechanism for the treatment of various inflammatory diseases.
[0004] MSC-exo is a substance with a unique subcellular structure secreted by MSC, which mediates some biological functions attributed to mesenchymal stem cells, such as tissue regeneration, immunomodulation and neuroprotection. Existing in vitro and in vivo experimental evidence shows that MSC-exo has anti-apoptosis, pro-angiogenesis and anti-fibrosis activities, especially showing immunomodulatory effects similar to those of source cells. In addition, compared with stem cell therapy, the use of exosomes has specific advantages and alleviates many safety issues. For example, MSC-exo reduces the potential risk of triggering immune responses and ectopic transplantation. At the same time, MSC-exo is small in size, has no risk of thrombosis, and has a variety of clinical applications. In addition to intravenous infusion, it can be easily assisted in clinical treatment by means of atomization, inhalation, tracheal infusion, local intervention, etc. Therefore, the development of skin treatment preparations that synergize its immunomodulatory properties and improve the therapeutic effect will enrich the clinical treatment methods of inflammatory skin diseases and bring treatment opportunities to improve the disease progression of patients, especially some hormone-dependent patients.
[0005] CN 109431910 B discloses a formula of a skin barrier repair composition for restoring the scalp barrier function and reducing its susceptibility, and its main component is a chemical substance. CN 109125107 B utilizes the synergistic effect of the composition polypeptides to propose a polypeptide composition for improving and repairing facial hormone-dependent dermatitis. CN 108379124 B discloses the invention of an essential oil for preventing and repairing skin barrier damage, which has a good anti-allergic effect on sensitive skin with abnormal skin barrier function. The above inventions mainly use cosmetic raw materials as the main functional ingredients. CN 111432799 A discloses the use of a composition with stem cell-derived exosomes as an effective ingredient in strengthening the skin barrier and improving its function, aiming to protect the skin barrier of the stratum corneum, strengthen the skin barrier of the stratum corneum and / or improve the skin barrier function by improving the skin barrier indicator lipids (such as improving the production of ceramide, dihydroceramide and / or sphingosine bases) and improving skin hydration. In the above-mentioned prior art documents, the formulas limited by chemical ingredients mostly achieve the auxiliary effect of improving the skin barrier by soothing allergies and reducing susceptibility. Summary of the invention
[0006] In view of the problems existing in the prior art, the primary purpose of the present invention is to provide a new therapeutic agent for inflammatory skin diseases - a stem cell-derived exosome (THC-exo) skin stabilizer loaded with tetrahydrocurcumin (THC). In the skin stabilizer, THC-exo and ectoin synergize with each other. Through scientific experimental ratios, no preservatives need to be added, and the in vitro stability of exosomes can be effectively increased. Compared with a single exosome preparation, the therapeutic effect is significantly improved.
[0007] The present invention also provides a method for preparing a THC-loaded stem cell-derived exosome (THC-exo) skin homeostatic agent.
[0008] Another object of the present invention is to provide an application of a THC-loaded stem cell-derived exosome skin homeostatic agent, which is effectively used to prevent, inhibit, alleviate or improve the damaged skin barrier function caused by various factors. The improvement of the skin barrier function is reflected in the direct promotion of the increase of skin barrier protein; and it can fundamentally improve cell function, maintain the microenvironment of damaged skin by clearing functionally damaged cells, and improve the continuous damaged state of the skin barrier.
[0009] To achieve the above objectives, the inventors have innovatively developed a set of preparation methods and applications of skin homeostatic agents through cell, animal and human experiments. The skin homeostatic agent can effectively treat inflammatory skin diseases or serve as an auxiliary treatment to reduce inflammatory mediators, enhance the secretion of skin barrier proteins, and maintain the normal detoxification function of skin cells. The above comprehensive effects will effectively improve the imbalance of skin homeostasis and achieve the effect of treating inflammatory skin diseases.
[0010] The technical solution adopted by the present invention is specifically:
[0011] The present invention provides a THC-loaded stem cell-derived exosome skin stabilizing agent, wherein the active ingredients of the skin stabilizing agent are THC-exo and ectoine.
[0012] The skin stabilizing agent provided by the present invention also includes a soothing agent and a moisturizing agent.
[0013] Furthermore, the skin stabilizer is composed of the following raw materials in percentage: THC-exo 10% (v / v), ectoine 0.2%-5.0% (w / v), soothing agent 0.5%-5% (w / v), moisturizing agent 0.01%-0.5% (w / v), and the balance is normal saline or sterile water.
[0014] The above-mentioned exosomes are exosomes secreted by stem cells, immune cells, plant cells, skin fibroblasts, etc.
[0015] The above-mentioned exosomes include exosomes or extracellular vesicles extracted by kit extraction, tangential flow, ultra-high speed centrifugation, density gradient centrifugation, size exclusion, etc. If it is not exhaustive, it is not limited to the above techniques.
[0016] More preferably, the anti-inflammatory active ingredient of the present invention is 0.2%-2% (w / v) of ectoine.
[0017] Further, the soothing agent is one or more of chamomile, allantoin, witch hazel, calendula, and Centella asiatica; more preferably, the soothing agent of the present invention is: 0.7%-5% (w / v) chamomile.
[0018] Furthermore, the moisturizing agent is glycerin, aloe vera gel or hyaluronic acid. More preferably, the moisturizing agent of the present invention is: hyaluronic acid of multiple molecular weight composition 0.1%-2.5% (w / v), molecular weight 3000-1 million.
[0019] Further preferably, the optimal composition of the skin stabilizing agent of the present invention is THC-exo with a final concentration of 2×10 9 Number of particles, mass fraction of other ingredients (w / v): Ectoine 1%, chamomile 0.8%, hyaluronic acid (3000 molecular weight) 0.6%, hyaluronic acid (50,000 molecular weight) 0.2%, hyaluronic acid (200,000-400,000 molecular weight) 0.2%, also includes inorganic or organic salts for adjusting osmotic pressure and buffering pH, other active ingredients, and the balance is normal saline.
[0020] The present invention also provides a method for preparing a THC-loaded stem cell-derived exosome skin homeostasis agent, comprising the following steps:
[0021] (1) Add THC-exo to a solvent to prepare a THC-exo suspension for later use;
[0022] (2) Mix ectoin, soothing agent and moisturizing agent in proportion, sterilize by high pressure steam sterilizer or radiation, mix the obtained solution with THC-exo suspension, maintain at 4°C, and perform aseptic operation; finally, adjust the pH of the solution with sterile buffer to obtain THC-exo skin stabilizer THC-exo-ect.
[0023] Furthermore, in step (1), the concentration of the THC-exo suspension is 2×10 8 -2×10 10 particles / mL.
[0024] Furthermore, in step (2), the pH is 6.8-7.2.
[0025] The present invention also provides a use of the above-mentioned THC-loaded stem cell-derived exosome skin homeostasis agent in the preparation of cosmetics or medicines for preventing, inhibiting, alleviating or improving damaged skin barrier function and improving cell function.
[0026] In the preparation process of the present invention, the solvent used is a buffer solution or physiological saline; the preferred buffer solution is a PBS buffer solution; meanwhile, the sterile buffer solution is a PBS buffer solution.
[0027] The composition according to one embodiment of the present invention can be prepared into various dosage forms, oral dosage forms, such as powders, pills, tablets, capsules, suspensions, emulsions, syrups, granules, elixirs, aerosols, and the like.
[0028] The composition according to one embodiment of the present invention can be prepared into a skin external preparation, a suppository, or a sterile injection solution.
[0029] The composition according to one embodiment of the present invention can be made into a cosmetic composition such as essence, powder (capsule, freeze-dried powder), emulsion, cream, gel, facial mask, dressing, etc.
[0030] The composition according to one embodiment of the present invention may be prepared as a pharmaceutical composition. When the composition according to one embodiment of the present invention is prepared as a pharmaceutical composition, the composition according to one embodiment of the present invention may be any preparation for oral or parenteral administration.
[0031] According to conventional methods, the pharmaceutical composition according to one embodiment of the present invention may include a pharmaceutically acceptable carrier, excipient or diluent.
[0032] The use of the pharmaceutical composition according to one embodiment of the present invention means that the desired material is introduced into the patient by any suitable method, and the pharmaceutical composition can be used by any general approach, as long as the material can reach the target tissue. For example, the pharmaceutical composition according to one embodiment of the present invention can be administered orally or parenterally. The approach for parenteral administration may include transdermal administration, intraperitoneal administration, intravenous administration, intraarterial administration, intralymphatic administration, intramuscular administration, subcutaneous administration, intradermal administration, topical administration, intrarectal administration, etc. However, the scope of the present invention is not limited thereto, and does not exclude multiple administration methods known in the art.
[0033] Defective skin barrier development occurs in inflammatory skin diseases, including AD and psoriasis. Compared with normal skin, patients with inflammatory skin diseases show increased transepidermal water loss (TEWL), decreased expression of skin barrier proteins, and abnormal immune responses in lesions, indicating decreased skin barrier function. As the main barrier to the external environment, an intact skin barrier is essential for maintaining tissue homeostasis. Therefore, the key to skin barrier repair lies in restoring skin barrier function and maintaining homeostasis in skin tissue, rather than simply enhancing the protective effect of the stratum corneum or improving hydration. Inflammatory skin diseases are associated with an imbalance in the skin's internal environment, including biochemical defects, imbalanced immune responses, and abnormalities in the cytokine system. External damage, such as damage caused by ultraviolet radiation, increases the formation of reactive oxygen species, damages DNA, lipids, and proteins, destroys the extracellular matrix (ECM), and promotes cell apoptosis and cell aging, thereby accelerating inflammatory damage. Skin cells of patients with skin barrier damage have dysfunction. How to restore normal cell function, ensure the balance of the skin microenvironment, and remove the imbalanced skin microenvironment such as cyclic inflammation and oxidative damage caused by apoptotic cells, which ultimately manifests as the restoration of barrier function, is the fundamental way to treat abnormal skin barrier function. In general, skin homeostasis is a series of pathological events that occur during the interaction between cells and the skin microenvironment. Its imbalance triggers cell dysfunction, which leads to the occurrence and development of skin diseases. Therefore, the present invention, starting from restoring the basic functions of skin cells, discloses a skin homeostatic agent that improves skin barrier function by maintaining the balance of skin homeostasis. And it is verified through examples that the invention can ultimately enhance the improvement of skin barrier protein FLG.
[0034] The present invention has the following advantages:
[0035] (1) Among the skin stabilizers provided by the present invention, ectoin can enhance skin hydration and promote permeation, while maintaining the stability of exosomes. Through the synergistic effects of THC-exo, ectoin and various excipients, it is superior to the simple application of exosomes in anti-inflammatory, enhancing barrier protein expression and improving cell function.
[0036] (2) The THC-exo prepared by the present invention has the effects of immunomodulation and restoring damaged cell functions, effectively reducing the expression of inflammatory mediators and regenerating damaged cells. THC-loaded stem cell-derived exosomes can enhance the expression of skin barrier protein FLG and effectively improve the repair effect of damaged skin barrier. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 This is a comparison of the electron microscopic morphology of THC-exo and THC-EVs.
[0038] Figure 2 This is a comparison chart of the population particle size of THC-exo and THC-EVs.
[0039] Figure 3 Detection diagram of vesicle marker proteins of THC-exo and THC-EVs.
[0040] Figure 4 is the loading ratio of tetrahydrocurcumin in THC-exo and THC-EVs.
[0041] Figure 5 This graph shows the effect of THC-exo concentration on HaCaT cell proliferation.
[0042] Figure 6 This is the cytotoxicity detection diagram of ectoine concentration.
[0043] Figure 7 Detection of FLG expression in the HaCaT UV-irradiated model.
[0044] Figure 8 To verify the efficacy of THC-exo skin homeostatic agent in repairing damaged tissue and improving tissue vitality in a 3D skin model.
[0045] Fig. 9 This is a comparison chart of the inhibition rate of inflammatory factors.
[0046] Fig.10 Figure 3. Protective and repairing ability of skin homeostatic agents to inhibit apoptotic cell generation.
[0047] Fig.11 Free radical scavenging function verification diagram.
[0048] Figure 12: New Zealand rabbit multiple skin irritation test.
[0049] Figure 13 Skin homeostatic agents reduce the rate of sensitization to irritants. DETAILED DESCRIPTION
[0050] The technical solution of the present invention is further explained and illustrated by means of specific embodiments below.
[0051] Example 1 Preparation of THC-loaded mesenchymal stem cells and THC-loaded exosomes
[0052] The preparation of MSC-encapsulated THC has been described in detail in (Patent No.: ZL 2021 1 0670023.3). Briefly: THC and mesenchymal stem cells are mixed in the order of increasing concentration gradient-temperature gradient and then incubated, and the culture medium is collected and purified. The culture medium is centrifuged at 10000g for 30 minutes to obtain a purified culture medium. The purified culture medium is added to a 30 KDa ultrafiltration tube, centrifuged at 4500rpm, 4°C for 2 hours, and a concentrate of THC-loaded exosomes (THC-Evs) is obtained. In order to remove large vesicles and impurities and obtain THC-exo with higher purity, the present invention will obtain purified THC-loaded exosomes through the following Example 2.
[0053] Example 2 Preparation of THC-exo
[0054] Example 1: THC-EVs were obtained and added to a container with low protein adsorption, diluted 20 times with pre-cooled PBS, filtered with a 0.22 μm filter, and the filtrate was added to an ultracentrifuge tube, the tube mouth was sealed, and centrifuged at 100,000g and 4°C for 90 min. The waste liquid was poured out, the precipitate was washed with pre-cooled PBS, and the supernatant was discarded after centrifugation at 100,000g and 4°C for 60 min. The precipitate was resuspended with pre-cooled saline, and the sample was retained for detection. The remainder was frozen at -80°C, which was THC-exo.
[0055] Example 3 Quality inspection comparison of THC-exo and THC-EVs
[0056] Morphology of THC-exo: Add sample solution to the sealing film, hold a piece of carbon-coated copper mesh with tweezers, and turn it upside down on the sample droplet. Wait for 1 min, carefully pick up the copper mesh with tweezers, and use filter paper to absorb the liquid on the surface of the copper mesh. Add 2% phosphotungstic acid dye solution to the sealing film for 30 seconds, turn the copper mesh upside down on the phosphotungstic acid dye solution, cover it on the droplet, wait for about 1 min, and use filter paper to absorb the liquid on the surface of the copper mesh. Place the copper mesh in the transmission electron microscope sample rod and observe the morphology of THC-exo and THC-EVs at an accelerating voltage of 80 kV, such as Figure 1 As shown: At the same magnification, the obtained solution contains a large number of exosomes with regular morphology and a typical teacup-like shape. THC-MVs contain certain non-vesicular substances (in the white box). The exosomes of THC-exo obtained by further ultracentrifugation are relatively uniform and have clearer composition.
[0057] Population size: Take 100 μl of THC-exo and THC-Evs samples, dilute to a concentration suitable for loading, and analyze the population size of the samples by nanoflow cytometry. After calibrating the instrument with 68-155 nm particle size standards, load 100 μl of each sample for testing. Figure 2By comparison, it can be seen that the population particle size of THC-MVs is relatively dispersed, and there are large vesicles, which meets the technical requirements. Compared with the improved technology, the population particle size of THC-exo is relatively uniform in the same sample. THC-exo medium particle size: THC-MVs medium particle size = 65.8: 77.2. It can be seen that the particle size of THC-exo is smaller, and large vesicles can be better removed. By enriching more THC-EVs to prepare THC-exo, the final concentration of THC-exo can reach 7.81×10 11 particles / mL, and the vesicle concentration in THC-MVs was about 6.9×10 9 particles / mL, which is about 1100 times different.
[0058] comprehensive Figure 1 , Figure 2 It can be seen that the THC-loaded exosomes prepared by the present invention have a particle size that conforms to the distribution of exosome populations, and electron microscopy shows that their morphology conforms to the typical characteristics of exosomes - teacup-like. In addition, the improved method can obtain an exosome solution with higher concentration, less impurities, and higher uniformity based on THC-EVs. This will enable more treatment methods with less dosage.
[0059] Example 4 Characteristic marker detection of THC-exo
[0060] Take THC-exo, THC-MVs, and MSC cell suspensions, lyse the vesicles with a special lysis buffer for exosome proteins, add 5× loading buffer (final concentration is 1×), mix well and boil for 5 min, and freeze the obtained protein at -20°C for later use. Load 10% SDS-PAGE gel, adjust the voltage to 80 V, the time is 20 min, and then set 100 V to run until bromophenol blue reaches the bottom of the separation gel. Transfer the protein to a PVDF membrane and block it with 5% milk overnight. Add primary antibody for incubation, wash 5 times with PBS, add secondary antibody for incubation, and develop color. Figure 3 As shown, the vesicle materials THC-exo and THC-MVs obtained by the two methods have the signature proteins CD9, CD81 and TSG 101, and the negative protein GM130 is not included in the extracted vesicles. In contrast, MSCs contain trace amounts of CD81, CD9 and TSG101 are negative, and GM130 is positive. By comparison, it can be found that the abundance of CD9, CD 81 and TSG101 in THC-exo is higher than that in THC-EVs, proving that the exosomes loaded with THC we obtained are of higher purity and concentration.
[0061] Example 5 THC content detection
[0062] THC-exo and THC-EVs samples were collected and diluted to 2×10 8 The sample was ultrasonically broken and centrifuged at 13000 rpm for 30 min at 4 °C. The concentration of THC was detected by LC-MS / MS. The method was the same as that in the patent (patent number: ZL 2021 10670023.3). Briefly:
[0063] Chromatographic conditions: Agilent SB C18 column (4.6 mm × 50 mm, 1.8 μm), column temperature 30 °C; mobile phase acetonitrile-water (50:50) containing 0.1% formic acid, flow rate 0.3 mL / min; injection volume 10 μL;
[0064] Mass spectrometry conditions: electrospray ionization source, positive ion mode, spray voltage source temperature of 100 ° C; nebulizer gas is nitrogen, nebulizer pressure is 40 psi; desolvation gas is nitrogen, temperature is 350 ° C, flow rate is 10L / mL; collision gas is high-purity nitrogen, pressure is 0.1MPa, multiple reaction monitoring (MRM) is used;
[0065] Standard curve: With the concentration of tetrahydrocurcumin as the horizontal axis and the peak area ratio of tetrachlorocurcumin and internal standard (diazepam) as the vertical axis, the mass of tetrahydrocurcumin contained in the sample is calculated.
[0066] The ratio of THC in the two samples was calculated according to the following formula: THC loading ratio = M0 / M×100%, where
[0067] M is the mass detection value of tetrahydrocurcumin in THC-exo sample (g / L),
[0068] M0 is the mass detection value of tetrahydrocurcumin in THC-Ev sample (g / L).
[0069] Through the detection of three batches, it was found that THC-exo / THC-Evs was 1.2, 2.1, 1.6, and the average was 1.63. This means that if the same number of vesicles is obtained, the loading rate of THC in THC-exo is higher, indicating that THC is mainly encapsulated in exo, because the exosomes in THC-exo are more uniform and have a higher concentration.
[0070] Example 6 Cytotoxicity Evaluation
[0071] HaCaT cells were cultured to 90% confluence, digested with trypsin, added to 96-well plates, 3000 cells / well, 6 parallels, and placed in an incubator at 37°C, 5% CO2. After the cells adhered to the wall, the corresponding sample treatment was added. After incubation for 48 hours, 10 μL CCK8 reaction solution was added to each well and incubated for another 4 hours. The light absorption value was measured at a wavelength of 450 nm using an ELISA reader. The relative proliferation rate (RGR) was calculated as follows: RGR = A / A0 × 100%
[0072] Where:
[0073] RGR——Relative growth rate, %;
[0074] A——absorbance of experimental group-blank;
[0075] A0——Absorbance of negative control group-blank.
[0076] like Figure 5 As shown, compared with the control group, the final concentration of THCexo was 2×10 8 -2×10 10 When , it can promote the proliferation of HaCaT cells, among which the optimal concentration is 2×10 9 In the following tests, a final concentration of 2×10 9 particles / mL of THC-exo compound ectoin, screen the best formula. Figure 6 It can be seen that compared with the THC-exo group, when the mass fraction of ectoin was between 0.2% and 3%, RGR%>100%, and there was no cytotoxicity. When the mass fraction of the composite ectoin was 0.5%-2%, ectoin could synergize with THC-exo to promote the proliferation of HaCaT cells, and the optimal concentration was 1%.
[0077] Example 7 Preparation of skin barrier stabilizer
[0078] It can be seen from Example 6 that the optimal dose of THC-exo is 2×10 9 particles / mL, ectoin content 1%.
[0079] The skin stabilizing agent of the present invention does not contain preservatives or hormones and is stored aseptically. The preparation method is as follows:
[0080] The THC-exo obtained in Example 2 was prepared in a sterile biosafety cabinet to prepare 2×10 10The suspension of particles / mL is ready for use, and the solvent is buffer, saline, etc. The mass fraction components are added according to the following formula: ectoin 1%, chamomile 0.8%, hyaluronic acid (3000 molecular weight) 0.6%, hyaluronic acid (50,000 molecular weight) 0.2%, hyaluronic acid (200,000-400,000 molecular weight) 0.2%, high pressure steam sterilizer or radiation sterilization. The resulting solution is mixed with THC-exo suspension in a biological safety cabinet at a ratio of 9:1. The process is maintained at 4°C and sterile. Finally, the solution pH is adjusted to 6.8-7.2 with a sterile buffer, which is a THC-exo skin stabilizer, recorded as THC-exo-ect.
[0081] Effect Example 1 Evaluation of Barrier Repair Function
[0082] (I) THC-exo and ectoin synergistically enhance barrier protein expression
[0083] Adherent human keratinocyte HaCaT cells were cultured in 1640 medium containing 10% fetal bovine serum. When the confluence was >90%, UVA / UVB ultraviolet rays, 70 mJ / cm 2 The cells were irradiated for 10 min and the samples to be tested were added, where exo was an equal amount of exosomes without THC obtained by the same method. The concentration of exosomes in Exo and THC-exo suspensions was consistent with that in the skin homeostatic agent, both of which were 2×10 9 particles / mL. The culture was continued at 37°C for 48 hr. The cells were collected by centrifugation at 300 rpm, washed with PBS, and lysed for WB detection. The detection method was the same as that in Example 4.
[0084] like Figure 7 As shown in the figure, after UV irradiation of HaCaT cells, the expression of FLG in the PBS group was significantly reduced compared with the control group (con). Compared with exo, THC-exo has a higher ability to promote FLG expression, and when added to cultured cells at the same time as 1% ectoin, the abundance of FLG is higher. It can be seen that THC, exo, and ectoin have a synergistic effect in restoring the function of skin barrier protein FLG.
[0085] 2. Evaluation of tissue activity and morphological ability
[0086] A 3D skin model was used to evaluate the tissue activity and tissue morphology restoration ability of the skin homeostatic agent.
[0087] Evaluation method: 0.2% sodium lauryl sulfate (SLS) was used to treat the 3D skin model (EpiKutis) to construct an inflammatory skin model with barrier damage. The groups are as follows:
[0088] Control group: PBS;
[0089] Model group: PBS+SLS;
[0090] Sample set 1: exo+SLS
[0091] Sample Group 2: THC-exo+SLS
[0092] Sample group 3: (THC-exo-ect) + SLS
[0093] 2 hours after applying SLS at a final concentration of 0.2% on the 3D skin model, add the test samples and control treatment. All samples are evenly distributed on the surface of the model and placed in an incubator (37°C, 5% CO2) for incubation for 24 hours. The 3D skin model culture fluid is collected and used for the ELISA kit in "Example 10" to detect inflammatory factors. The skin model is moved into the corresponding well plate, and the cell viability is detected using the MTT kit. After the MTT incubation, the outer surface of the model is washed with PBS, moved into a new well plate, isopropanol is added, and the plate is sealed and shaken. The model is pierced, the isopropanol extract is aspirated, and the absorbance (OD) value is read at a wavelength of 570nm on a microplate reader. The blank is an isopropanol solution. The relative tissue viability of each test group is calculated according to the following formula:
[0094] (OD of drug well - OD of blank well) / (OD of control well - OD of blank well) = tissue viability (%)
[0095] like Figure 8 As shown in the figure, SLS can effectively reduce the vitality of the skin tissue in the model group, with a significance of ###. When THC-exo or THC-exo skin stabilizer is used for treatment, it can repair the damaged skin tissue to varying degrees. Compared with the model group, the significance is *, p<0.5 or **, p<0.01. Compared with pure THC-exo, it can be seen that the skin stabilizer prepared by the invention formula has a better effect.
[0096] Effect Example 2 Application Example of Evaluation of Inflammatory Factor Inhibition Function
[0097] 1. Evaluation of the inhibitory effect of inflammatory factors
[0098] The 3D skin model culture fluid obtained in "Effect Example 1" was used to detect the inflammatory factors IL-1β, IL-6, IL-8, TNF-α, and PGE2 using an ELISA kit. Inflammatory factor inhibition rate = (inflammatory factor content in the sample - inflammatory factor content in the control group) / inflammatory factor content in the control group × 100%. Fig. 9As shown, each group of samples has a consistent effect on inflammatory factors to varying degrees. The inflammatory inhibition effect of THC-exo and THC-exo-etc steady-state agents is more obvious than that of the exo group. Significantly, the inhibitory ability of THC-exo-etc steady-state agents on PGE2, TNF-α, and IL-1β is higher than that of other groups.
[0099] Effect Example 3 Restoring Cell Detoxification Function and Maintaining Skin Homeostasis Function Evaluation
[0100] 1. Evaluation of the ability to inhibit cell apoptosis
[0101] HaCaT cells were collected, transferred to six-well plates, and cultured at 37°C, 5% CO2 for 24 hr.
[0102] UV irradiation
[0103] 1) Protection: After the cells in the six-well plate were washed with PBS, treatment groups were set up, and different concentrations of the samples to be tested were added and cultured for 48 hours. After 48 hours, they were irradiated at a distance of 15 cm from the UV irradiator for 5 minutes and cultured for another 18 hours.
[0104] 2) Repair: Irradiate the cells at a distance of 15 cm from the UV irradiator for 5 min. After irradiation, wash the cells with PBS, add different concentrations of the test samples, and continue to culture for 18 hr.
[0105] Detection
[0106] Collect the cells, discard the supernatant by centrifugation, resuspend in PBS, wash once, resuspend in 100 ul 1*Binding buffer, add 5 ul FITC-Annexin V, incubate at room temperature for 15 min, wash, resuspend in 1*Binding buffer after centrifugation, add PI, incubate for 5 min, wash with 1*Binding buffer, filter after washing, and use flow cytometry to detect the protection and repair ability of cell apoptosis.
[0107] Depend on Fig.10 It can be seen that ultraviolet rays can cause apoptosis of HaCaT cells. There is no significant difference in the protection and repair ability of THC-exo and exo against UV damage. When THC-exo is combined with ectoin, the protection effect against UV is significant, and it also shows the effect of reducing cell apoptosis after UV damage.
[0108] 2. Evaluation of OH scavenging capacity
[0109] Take several 50 mL centrifuge tubes and add samples according to the following (mL) Table 1. The concentrations refer to the concentrations prepared above.
[0110] Table 1. Sample volume table
[0111]
[0112] React at 37℃ for 30min, cool, and centrifuge at 2000 rpm / min for 10min. Take the supernatant to a 96-well ELISA plate, 200ul per well, and measure the absorbance (OD) at a wavelength of 510nm on an ELISA reader. Set up 3 replicate wells for each concentration, and repeat the experiment 3 times. Calculate the hydroxyl radical scavenging rate according to the following formula.
[0113] Hydroxyl free radical scavenging rate = A blank control group - (A sample group - A sample control group) / A blank control group * 100%.
[0114] The skin microenvironment of patients with inflammatory skin diseases leads to impaired cell function and increased reactive oxygen species, which in turn aggravates the inflammatory response, destroys skin function, and exacerbates the progression of inflammatory skin diseases. Through the ·OH scavenging experiment, compared with Vc (100μg / mL) with significant antioxidant activity, the scavenging rate of THC-exo for ·OH was significantly improved (about 1.5 times); the scavenging rate of THC-exo-etc for ·OH was more than twice that of 100μg / mL Vc, which was equivalent to 200μg / mL Vc (both > 90%), and was close to 100%, see for details Fig.11 The above results show that the skin stabilizer can effectively resist oxidation, clear excess hydroxyl free radicals, maintain the homeostasis balance of the skin, and improve the detoxification ability of skin cells.
[0115] Effect Example 4 Multiple Skin Irritation Evaluation
[0116] New Zealand rabbits were shaved and skin was prepared. The back skin of each rabbit was divided into four areas, and 0.5 mL PBS and test group samples were applied to each area twice a day for 14 days for irritation test. The skin reactions of the test rabbits were recorded and the corresponding scores were recorded as shown in Table 2 below. Fig.12 It can be seen that neither THC-exo nor THC-exo-ect causes skin irritation.
[0117] Table 2. Results of multiple skin irritation tests on New Zealand rabbits
[0118]
[0119] Note: 4 animals were counted in each group of samples
[0120] Effect Example 5 Protection against common irritants
[0121] Ten subjects were tested with PBS (control group) or skin stabilizer on the front of their arms, and then a patch test with irritants was performed. The statistical data of the subjects showed that the irritant-induced damage to the skin in the smeared area was greatly reduced, indicating that the skin stabilizer of the present invention can protect the integrity of the epidermal cell membrane structure and barrier function to a certain extent, improve the skin's tolerance, and has the effect of repairing damaged skin and alleviating allergic symptoms ( Fig.13 ).
Claims
1. A THC-loaded stem cell-derived exosome skin homeostasis agent, characterized in that: The raw materials are composed of the following percentages: stem cell exosomes loaded with tetrahydrocurcumin THC-exo 10% v / v, ectoine 0.2%-5.0% w / v, soothing agent 0.5%-5% w / v, moisturizing agent 0.01%-0.5% w / v, and the balance is normal saline or sterile water; The tetrahydrocurcumin-loaded stem cell-derived exosomes are prepared by the following method: adding THC-loaded exosomes to a container with low protein adsorption, diluting 20 times with pre-cooled PBS, filtering with a 0.22 μm filter, adding the filtrate to an ultracentrifuge tube, sealing the tube mouth, centrifuging at 100,000 g, 4°C for 90 min; dumping the waste liquid, washing the precipitate with pre-cooled PBS, centrifuging at 100,000 g, 4°C for 60 min, and discarding the supernatant; resuspending the precipitate with pre-cooled saline, retaining the sample for detection, and freezing the remainder at -80°C, which is THC-exo; The soothing agent is one or more of chamomile, allantoin, witch hazel, calendula, and Centella asiatica; the moisturizing agent is glycerin, aloe vera gel, or hyaluronic acid; The THC-loaded stem cell-derived exosome skin homeostasis agent is prepared by the following method: (1) Add THC-exo to buffer to prepare THC-exo suspension for later use; (2) Mix ectoine, soothing agent and moisturizing agent in proportion, sterilize by high pressure steam sterilizer or radiation, mix the obtained solution with THC-exo suspension, maintain at 4°C, and operate aseptically; finally, adjust the pH of the solution to 6.8-7.2 with sterile buffer to obtain THC-exo skin stabilizer; The concentration of the THC-exo suspension is 2×10 8 -2×10 10 particles / mL.
2. Use of the THC-loaded stem cell-derived exosome skin homeostasis agent as claimed in claim 1 in the preparation of cosmetics or medicines for repairing skin barrier function.
